Neuromodulation perception by the general public — first large-scale survey reveals high awareness but low understanding
Summary
A Nature Scientific Reports study of 2,847 adults from 12 countries found that 78% had heard of brain stimulation therapies but only 23% could correctly describe how any specific neuromodulation technology works. Awareness was highest for DBS (71%) and TMS (58%), both boosted by celebrity coverage. Concern about side effects was the primary barrier to acceptance (67%). Forty-four percent said they would consider neuromodulation for a severe neurological condition, but only 12% would consider it for cognitive enhancement.
Why it matters
The willingness-to-treat vs willingness-to-enhance gap — 44% vs 12% — reveals a significant market insight: public acceptance of neuromodulation is condition-dependent, not technology-dependent. This has direct commercial implications: neuromodulation companies should lead with clinical benefit for serious conditions rather than cognitive enhancement framing, even if their long-term commercial vision includes enhancement applications.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial